Circulating and progenitor endothelial cells are abnormal in patients with different types of von Willebrand disease and correlate with markers of angiogenesis

American Journal of Hematology

Volumn 86, Issue 8, 2011, Pages 650-656

  Gritti, Giuseppe ^a   Cortelezzi, Agostino ^a   Bucciarelli, Paolo ^a   Rezzonico, Francesca ^a   Lonati, Silvia ^a   La Marca, Silvia ^a   Silvestris, Ilaria ^a   Federici, Augusto B ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; CD146 ANTIGEN; CD31 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ERYTHROPOIETIN; PADGEM PROTEIN; THROMBOPOIETIN; VASCULOTROPIN;

ADULT; ANGIOGENESIS; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STEM CELL; UPREGULATION; VON WILLEBRAND DISEASE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CELL COUNT; CHILD; COHORT STUDIES; CROSS-SECTIONAL STUDIES; CYTOKINES; E-SELECTIN; ENDOTHELIAL CELLS; FEMALE; HUMANS; ITALY; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; STEM CELLS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTORS; VON WILLEBRAND DISEASES; YOUNG ADULT;

EID: 79960382274     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22070     Document Type: Article

References (34)

1. Sadler JE, Budde U, Eikenboom JC, et al. Update on the pathophysiology and classification of von Willebrand disease: A report of the subcommittee on von Willebrand factor. J Thromb Haemost 2006; 4: 2103-2114.
2. Ruggeri ZM. Von Willebrand Factor-Looking back and looking forward. Thromb Haemost 2007; 98: 55-62.
3. Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 2008; 112: 11-18.
4. Tomer A. Human marrow megakaryocyte differentiation: multiparameter correlative analysis identifies von Willeband factor as a sentitive and distinctive marker for early (2N and 4N) megagakaryocytes. Blood 2004; 104: 2722-2727.
5. Dunois-Larde C, Capron C, Fichelson S, et al. Exposure of human megakaryocytes to high shear rates accelerates platelet production. Blood 2009; 114: 1875-1883.
6. Nurden P, Nurden AT, La Marca S, et al. Platelet morphological changes in 2 patients with von Willebrand disease type 3 caused by large homozygous deletion of von Willebrand factor gene Abnormal Morphology in VWD3. Haematologica 2009; 94: 1627-1629.
7. Nurden P, Gobbi G, Nurden A, et al. Abnormal VWF modifies megakaryocytopoiesis: Studies of platelets and megakaryocyte cultures from patients with von Willebrand disease type 2B. Blood 2010; 115: 2649-2656.
8. Nurden A, Federici AB, Nurden P. Altered megakaryocytopoiesis in von Willebrand disease type 2B. J Thromb Haemost 2009; Suppl 1: 277-281.
9. Blann AD, Woywodt A, Bertolini F, et al. Circulating endothelial cells. Biomarker of vascular disease. Thromb Haemost 2005; 93: 228-235.
10. Bertolini F, Shaked Y, Mancuso P, Kerbel RS. The multifaceted circulating endothelial cell in cancer: Towards marker and target identification. Nat Rev 2006; 6: 835-845.
11. Del Papa N, Colombo G, Fracchiolla N, et al. Circulating endothelial cells as a marker of ongoing vascular disease in systemic sclerosis. Arthritis Rheum 2004; 50: 1296-1304.
12. Mutin M, Canavy I, Blann A, et al. Direct evidence of endothelial injury in acute myocardial infarction and unstable angina by demonstration of circulating endothelial cells. Blood 1999; 93: 2951-2958.
13. Solovey A, Lin Y, Browne P, et al. Circulating activated endothelial cells in sickle cell anemia. N Engl J Med 1997; 337: 1584-1590.
14. Urbich C, Dimmeler S. Endothelial progenitor cells: Characterization and role in vascular biology. Circ Res 2004; 95: 343-353.
15. Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005; 353: 999-1007.
16. Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348: 593-600.
17. Vasa M, Fichtlscherer S, Aicher A, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001; 89: E1-7.
18. Massa M, Rosti V, Ramajoli I, et al. Circulating CD34+, CD133+, and vascular endothelial growth factor receptor2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasia. J Clin Oncol 2005; 23: 5688-5695.
19. Cortelezzi A, Fracchiolla NS, Mazzeo LM, et al. Endothelial precursors and mature endothelial cells are increased in the peripheral blood of myelodysplastic syndromes. Leuk Lymphoma 2005; 46: 1345-1351.
20. Oppliger Leibundgut E, Horn MP, Brunold C, et al. Hematopoietic and endothelial progenitor cell trafficking in patients with myeloproliferative diseases. Haematologica 2007; 92: e47.
21. Cortelezzi A, Gritti G, Del Papa N, et al. Pulmonary arterial hypertension in primary myelofibrosis is common and associated with an altered angiogenic status. Leukemia 2008; 22: 646-649.
22. Della Porta MG, Malcovati L, Rigolin GM, et al. Immunophenotypic, cytogenetic and functional characterization of circulating endothelial cells in myelodysplastic syndromes. Leukemia 2008; 22: 530-537.
23. Santilli F, Romano M, Recchiuti A, et al. Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients. Blood 2008; 112: 1085-1090.
24. Alonci A, Allegra A, Bellomo G, et al. Evaluation of circulating endothelial cells, VEGF and VEGFR2 serum levels in patients with chronic myeloproliferative diseases. Hematol Oncol 2008; 26: 235-239.
25. Biguzzi E, Mancuso Franchi F, Calleri A, et al. Circulating Endothelial Cells (CECs) and progenitors (CEPs) in severe hemophiliacs with different clinical phenotype. Br J Haematol 2009; 144: 803-805.
26. Mancuso P, Antoniotti P, Quarna J, et al. Validation of a standardized method for enumerating circulating endothelial cells and progenitors: Flow cytometry and molecular and ultrastructural analyses. Clin Cancer Res 2009; 15: 267-273.
27. Del Papa N, Cortiana M, Vitali C, et al. Simvastatin reduces endothelial activation and damage but is partially ineffective in inducing endothelial repair in systemic sclerosis. J Rheumatol 2008; 35: 1323-1328.
28. Conway DS, Pearce LA, Chin BS, et al. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation 2003; 107: 3141-3145.
29. Morange PE, Simon C, Alessi MC, et al. Endothelial cell markers and the risk of coronary heart disease: The prospective epidemiological study of myocardial infarction (PRIME) study. Circulation 2004; 109: 1343-1348.
30. Fuster V, Fass DN, Kaye MP, et al. Arteriosclerosis in normal and von Willebrand pigs: Long-term prospective study and aortic transplantation study. Circ Res 1982; 51: 587-593.
31. Badimon L, Steele P, Badimon JJ, et al. Aortic atherosclerosis in pigs with heterozygous von Willebrand disease. Comparison with homozygous von Willebrand and normal pigs. Arteriosclerosis 1985; 5: 366-370.
32. Nichols TC, Bellinger DA, Reddick RL, et al. von Willebrand factor does not influence atherogenesis in arteries subjected to altered shear stress. Arterioscle Thromb Vasc Biol 1998; 18: 323-330.
33. Sramek A, Bucciarelli P, Federici AB, et al. Patients with type 3 severe von Willebrand disease are not protected against atherosclerosis: Results from a multicenter study in 47 patients. Circulation 2004; 109: 740-744.
34. Denis CV, Andre P, Saffaripour S, Wagner DD. Defect in regulated secretion of P-selectin affects leukocyte recruitment in von Willebrand factor-deficient mice. Proc Natl Acad Sci U S A 2001; 98: 4072-4077.